Lung Cancer Screening Eligibility Assessment

NCT06133816 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6125

Last updated 2025-05-31

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.

Conditions

Interventions

BEHAVIORAL

Framed Introductory Message A

Randomly assign patients to receive introductory message encouraging them to complete the survey (version A).

BEHAVIORAL

Framed Introductory Message B

Randomly assign patients to receive introductory message encouraging them to complete the survey (version B).

BEHAVIORAL

Framed Introductory Message C

Randomly assign patients to receive introductory message encouraging them to complete the survey (version C).

BEHAVIORAL

Framed Tobacco Use Message A

Randomly assign patients to receive norming message related to tobacco use (version A).

BEHAVIORAL

Framed Tobacco Use Message B

Randomly assign patients to receive norming message related to tobacco use (version B).

BEHAVIORAL

Financial Incentive

Randomly assigned patients to be entered into a drawing to receive a $100 gift card.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH
  • National Cancer Institute (NCI)

    collaborator NIH
  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Katharine A Rendle, PhD,MSW,MPH · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2024-01-31
Completion
2024-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06133816 on ClinicalTrials.gov